Oxcarbazepine and adverse events: Impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy

Functional Neurology

Volumn 23, Issue 2, 2008, Pages 97-100

  Ortenzi, Andrea ^a   Paggi, Aldo ^a   Foschi, Nicoletta ^a   Sabbatini, Deborah ^a   Pistoli, Emore ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Adverse events; Epilepsy; Mono hydroxy derivative; Oxcarbazepine

Indexed keywords

OXCARBAZEPINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPONATREMIA; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; OUTCOME ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; VISUAL DISORDER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES;

EID: 50849132592     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Passarella B, Nozzoli C. Long-term treatment with oxcarbazepine in clinical practice. Funct Neurol 2005;20:131-133
2. Schimdt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2005;5:627-635
3. Albani F, Bisulli F, Bartezaghi M, Turrini R, Baruzzi A and the SECONDO Study Group. Multicentre observational study evaluating immediate and progressive switching from carbamazepine to oxcarbazepine in patients with epilepsy. Funct Neurol 2007;22:111-115
4. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003;42:1023-1042
5. Sallas WM, Milosavljev S, D'Souza J, Hossain M. Pharmacokinetic drug interaction in children taking oxcarbazepine. Clin Pharmacol Ther 2003;74:138-149
6. Friis ML, Kristensen O, Boas J et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993;87:224-227
7. Barcs G, Walker EB, Elger CE et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597-1607
8. Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001;21:904-919
9. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000;55:697-705
10. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000;38:191-204
11. Sachdeo R, Beydoun A, Schachter S et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001;57:864-871
12. Striano S, Striano P, Di Nocera P et al. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. Epilepsy Res 2006;69:170-176
13. Sachdeo RC, Wassertein AG, D'Souza J. Oxcarbazepine (Trileptal) effect on serum sodium. Epilepsia 1999;40(Suppl 7): 103 [Abstract]
14. Ramsay RE, Pryor F. Epilepsy in the elderly. Neurology 2000;55 (Suppl 1):S9-14
15. Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of carbazepine in elderly patients with epilepsy. Epilepsy Behav 2003;4:175-180
16. Levert H, Odou P, Robert H. LC determination of oxcarbazepine and its active metabolite in human serum. J Pharm Biomed Anal 2002;28:517-525